News
Regeneron's Dupixent leads growth as Eylea sales decline. Oncology focus grows. Valuation attractive, but growth delayed by 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback